FDA provides clearance for MR-Linac; Froedtert & MCW, MD Anderson will be first in U.S. to treat patients
Dec. 6, 2018 MCW News - Since 2017, Froedtert & the Medical College of Wisconsin have been conducting ground-breaking research using the Elekta Unity MR-linac, a breakthrough technology for cancer treatment. Today, we are excited to share that the MR-linac has received Food and Drug Administration (FDA) clearance for patient treatment. The first patients in the U.S. to be treated using this highly precise radiation therapy will be treated at the Froedtert & MCW Clinical Cancer Center at Froedtert Hospital and M.D. Anderson in Texas.
“Unity is a tremendous leap forward in our ability to tailor radiation therapy to each patient’s tumor and anatomy and to adapt treatment in real time as the tumor changes shape and position relative to organs at risk,” said Christopher Schultz, MD, Medical College of Wisconsin, Bernard and Miriam Peck Family Professor and Chairman of the Department of Radiation Oncology, at the Froedtert & MCW Cancer Network and Chair of the Elekta MR-linac Consortium. “I believe this enabling technology will fundamentally transform how radiation therapy regimens are developed, implemented and adapted to achieve optimal outcomes for our patients. We are excited to offer Unity to our patients and are proud of our contributions to making this technology a clinical reality.”
Keep up with the latest news. Sign up for Newsroom Alerts.
Latest press releases, stories and resources.